share_log

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71

JMP证券维持Halozyme Therapeutics的市场跑赢大盘,将目标股价下调至71美元
Benzinga ·  05/08 13:58

JMP Securities analyst Jason Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and lowers the price target from $72 to $71.

JMP Securities分析师杰森·巴特勒维持Halozyme Therapeutics(纳斯达克股票代码:HALO)的市场跑赢大盘,并将目标股价从72美元下调至71美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发